Low-dose nivolumab in advanced hepatocellular carcinoma

BMC Cancer

Table 4 Univariate and multivariate analysis results for PFS in 78 patients with advanced hepatocellular carcinoma who received low-dose nivolumab

Characteristics	No. of patients	Univariate		Multivariate
Characteristics	No. of patients	PFS (months)	P value	HR (95% CI)	P value
Age
< 60 years	29 (37.2%)	2.3	0.68
≥ 60 years	49 (62.8%)	2.4
Sex
Male	61 (78.2%)	2.4	0.99
Female	17 (21.8%)	2.4
ECOG PS
0	34 (43.6%)	2.3	0.11
1	44 (56.4%)	2.4
Child–Pugh classification
A	58 (74.4%)	2.3	0.29
B (7)	20 (25.6%)	2.4
ALBI grade
1	33 (42.3%)	2.2	0.56
2	45 (57.7%)	2.4
Hepatitis B
Yes	49 (62.8%)	2.4	0.27
No	29 (37.2%)	2.4
Hepatitis C
Yes	23 (29.5%)	2.3	0.48
No	55 (70.5%)	2.4
Macrovascular invasion (IVC, HV, PV)
Yes	39 (50%)	2.4	0.43
No	39 (50%)	2.4
Main portal vein thrombosis
Yes	11 (14.1%)	2.2	0.09
No	67 (85.9%)	2.4
History of hepatectomy
Yes	31 (39.7%)	2.5	0.13
No	47 (60.3%)	2.3
Extrahepatic spread
Yes	39 (50%)	2.0	0.06
No	39 (50%)	2.6
Lymph node metastasis
Yes	27 (34.6%)	2.5	0.51
No	51 (65.4%)	2.2
Nivolumab dose
20 mg	17 (21.8%)	4.5	0.007*	0.43 (0.22–0.81)	0.009*
100 mg	61 (78.2%)	2.3
Treatment lines
Second line	45 (57.7%)	2.4	0.46
Third line and later lines	33 (42.3%)	2.3
AFP ≥ 400 ng/ml
Yes	41 (52.6%)	2.4	0.41
No	37 (47.4%)	2.3

PFS Progression-free survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, BCLC Barcelona-Clinic Liver Cancer, ALBI Albumin-Bilirubin, IVC Inferior vena cava, HV Hepatic vein, PV Portal vein, AFP Alpha-fetoprotein. All status mentioned above were determined at the time of nivolumab initiation. *Statistical difference

ISSN: 1471-2407